Keeping an eye on this.
RedHill secures funding for Phase 2 study of COVID-19 treatment
RedHill said it has received new non-dilutive external funding for a Phase 2 study of its oral antiviral drug RHB-107 in the treatment of early COVID-19. The Israeli company said the approximately $4.8M in funding will cover the entirety of the RHB-107 arm of the ACESO PROTECT study for early COVID-19 outpatient treatment. The study, which will have 300 patients, is expected to begin enrollment in the coming weeks and be completed by the end of 2024. If approved, the product could provide an additional option to Pfizer’s Paxlovid in the early COVID-19 treatment space, RedHill said. More on RedHill RedHill stock nearly doubles in value pre-market on a five-year FDA exclusivity grant Financial information for RedHill
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Like
Report
Login to post
No comments yet